Interferon-induced depression and peripheral blood serotonin in patients with multiple sclerosis

Close metadata

Recommended articles:

The effect of insomnia on mild cognitive impairment in patients with vascular risks: results of a three-year longitudinal study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3-2):30-36

The association of polymorphisms of the serotonin transporter gene SLC6A4 with depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(2):135-139

Validation of e-version of Russian-language expanded disability status scale (EDSS) for patients with multiple sclerosis in the Russian Federation. Medical Technologies. Assessment and Choice. 2024;(1):9-16

A perspective on the application of CRISPR/CAS9 genome editing system to study of molecular-genetic basis of mental disorders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33

The effectiveness of tele-rehabilitation for patients with multiple sclerosis during the COVID-19 pandemic in 2020—2021 was evaluated in this study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):75-81

Validation of screening method based on EEG analysis for the risk assessment of psychiatric and behavioral disorders: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):88-96

A clinical case of the new-onset bipolar affective disorder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129

Pathogenetic basis of modern approaches to the therapy of sleep disorders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74

Features of the clinical picture of affective disorders in women during the menopausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):86-96

Objective. To study the dynamics of anxiety-depressive disorders and peripheral blood serotonin in patients with multiple sclerosis (MS) during interferon-ß (IFN-ß) therapy. Material and methods. The level of anxiety and depression in 227 MS patients was measured by psychometric testing at baseline and during treatment. The concentration of serotonin in serum of patients was determined by enzyme immunoassay. Results. The presence of emotional disorders in patients with MS was confirmed. Their relationship with personality characteristics of the patient, the course of the disease and social status was shown. The level of humoral serotonin was lower in patients with MS. The relationship between the serotonergic system deficiency in patients with MS and anxiety disorders was shown. Interferon-induced depression was not associated with serotonin metabolism. It is a multifactor condition influenced by the patient’s initial emotional level, personality characteristics, psychological reaction to therapy and the unfavorable dynamics of the disease. Conclusion. IFN-β does not appear to induce depression in MS patients.

Keywords:

multiple sclerosis

IFN-β

anxiety

depression

serotonin

Authors:

Baĭdina T.V.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

Trushnikova T.N.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera", Perm'

SPIN RSCI: 6200-1697
Scopus AuthorID: 55843664200
ORCID: 0000-0001-9199-7392

Danilova M.A.

GBOU VPO "Permskaia gosudarstvennaia meditsinskaia akademiia im. akad. E.A. Vagnera" Minzdrava RF, Perm'

ORCID: 0000-0002-2746-5567

List of references:

Kesselring J, Klement U. Cognitive and affective disturbances in multiple sclerosis. J Neurol. 2001;248(3):180-183. https://doi.org/10.1007/s004150170223
Baidina TV, Kuklina EM, Trushnikova TN, Pichkaleva YuA, Sursyakova NV, Danchenko IYu, Medvedeva EL, Foteeva AV. Pathogenetic and clinical peculiarities of disseminated sclerosis. Perm Med J. 2016;33(4):17-22. (In Russ.) https://elibrary.ru/item.asp?id=26685037
Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942-947. https://doi.org/10.1038/sj.mp.4001119
Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. 2000;18(11):2316-2326. https://doi.org/10.1200/jco.2000.18.11.2316
The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 1993;43(4):655-661. https://doi.org/10.1212/wnl.43.4.655
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology. 1995;45(7):1277-1285. https://doi.org/10.1212/wnl.45.7.1277
Goeb JL, Even C, Nicolas G, Gohier B, Dubas F, Garré JB. Psychiatric side effects of interferon-beta in multiple sclerosis. Eur Psychiatry. 2006;21(3):186-193. https://doi.org/10.1016/j.eurpsy.2005.09.013
Patten SB, Williams JV, Metz LM. Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis. Mult Scler. 2008;14(3):406-411. https://doi.org/10.1177/1352458507082942
Zephir H, Seze J, Stojkovic T, Delisse B. Multiple sclerosis and depression: influence of interferon beta therapy. Mult Sclerosis J. 2003;9(3):284-288. https://doi.org/10.1191/1352458503ms915oa
Arnett PA. Longitudinal course of depression symptoms in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2006;77(5):606-610. https://doi.org/10.1136/jnnp.2004.047712
Goeb JL, Cailleau A, Laine P. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol. 2003;26(1):5-7. https://doi.org/10.1097/00002826-200301000-00002
Pandya R, Patten S. Depression in multiple sclerosis associated with interferon beta-1a (Rebif). Can J Psychiatry. 2002;47(7):686. https://doi.org/10.1177/070674370204700720
de Long HJL, Kingwell E, Shirani A, Tervaert CJW, Hupperts R, Zhao Y, Zhu F, Evans C, van der Kop ML, Traboulsee A, Gustafson P, Petkau J, Marrie RA, Tremlett H. Evaluating the safety of β-interferons in MS: A series of nested case-control studies. Neurology. 2017;88(24):2310-2320. https://doi.org/10.1212/wnl.0000000000004037
Akintseva YV, Baidina TV. Platelet serotonin in patients with multiple sclerosis. Vrach-aspirant. 2011;48 (5, 4):614-619. (In Russ.)
Myint AM, Schwarz MJ, Steinbusch HW, Leonard BE. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab Brain Dis. 2008;24(1):55-68. https://doi.org/10.1007/s11011-008-9114-5
Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000;18(11):2316-2326. https://doi.org/10.1200/jco.2000.18.11.2316
Mirsky MM, Marrie RA, Rae-Grant A. Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy. Int J MS Care. 2016;18(6):305-310. https://doi.org/10.7224/1537-2073.2016-056
Schippling S, O’Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung H, Comi G, Jeffery DR, Kappos L, Goodin DS, Arnason B. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016;263(7):1418-1426. https://doi.org/10.1007/s00415-016-8146-8
Kirzinger SS, Jones J, Siegwald A, Crush AB. Relationship between disease-modifying therapy and depression in multiple sclerosis. Int J MS Care. 2013;15(3):107-112. https://doi.org/10.7224/1537-2073.2012-036
Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, Gasperini C. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study. COGIMUS Study Group. Mult Scler. 2011;17(8):991-1001. https://doi.org/10.1177/1352458511401943
Patten SB. What is the best approach to treating in-terf eron-induced depression in people with multiple sclerosis? J Neurosci. 2001;26:66-69.
Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol. 2000;18(11):2316-2326. https://doi.org/10.1200/jco.2000.18.11.2316

Close metadata